Neohepatect (Human Hepatitis B Immunoglobulin)

Human Hepatitis B Immunoglobulin, the active ingredient in Neohepatect, is an immunoglobulin presented as a sterile solution for intravenous use. It supplies passive immunity by delivering anti‑HBs antibodies to individuals at risk of hepatitis B infection, such as after occupational exposure, accidental needle sticks, or in the setting of liver transplantation.

GNH USA supplies Neohepatect as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, pharmacies and clinics worldwide. The company follows stringent quality standards and provides regulatory documentation to support import and clinical use.

Neohepatect, a hepatitis B immune globulin, acts within the antiviral pathway to provide immediate passive protection against hepatitis B virus.

Post‑exposure prophylaxis of hepatitis B: delivers anti‑HBs antibodies to individuals who have been exposed to HBV, reducing the risk of infection. Prevention of hepatitis B recurrence after liver transplantation: supplies high‑titer antibodies to protect the transplanted liver graft from viral re‑infection. Pre‑transplant prophylaxis for HBV‑negative recipients of grafts from HBV‑positive donors: provides immunity before transplantation to prevent de novo infection.

Neohepatect may be associated with a range of adverse reactions, most of which are infusion‑related or immune‑mediated.

Common Side Effects: - Fever - Headache - Nausea - Injection site reactions (e.g., redness, swelling)

Serious or Rare Side Effects: - Anaphylactic reaction - Serum sickness - Severe hypotension

Prior to using Neohepatect, several precautionary measures should be observed to ensure patient safety and product integrity.

Screen for HBV immunity: assess anti‑HBs status before infusion. Monitor for allergic reactions: observe patient during and after the intravenous administration. Use with caution in immunocompromised patients: immune response may be altered. Avoid concurrent administration with live vaccines: may interfere with vaccine efficacy. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Neohepatect can interact with other medicines or biologics; awareness of these interactions helps optimize therapy.

Major Interactions (Avoid): - Concurrent use of immunoglobulin products with live viral vaccines: may reduce vaccine efficacy. - Co‑administration with other anti‑HBs‑containing blood products: risk of antibody overload.

Moderate Interactions (Monitor Closely): - Combination with antiviral agents such as entecavir or tenofovir: monitor HBV DNA levels for additive effect. - Use with immunosuppressants (e.g., tacrolimus, cyclosporine): may affect graft immunity and antibody persistence. - Concurrent high‑dose corticosteroids: may blunt the immunoglobulin’s protective effect.